At what dose does 2-FA produce psychosis?

Effects like psychosis are typically reported at common doses and above. A common oral dose of 2-FA is 30–50 mg.

What other substances cause psychosis?

Other substances documented to produce psychosis include 1P-ETH-LAD, Methamphetamine, 3,4-CTMP, 1P-LSD, Myristicin, and 35 more.

Psychosis from 2-FA — Detailed Guide

Q: Does 2-FA cause psychosis?

Yes. Psychosis is a documented cognitive effect of 2-FA. Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — characterized by firmly held false beliefs (delusions), perception of things that are not there (hallucinations), disorganized thought and speech, and a loss of the ability to distinguish internal mental events from external reality.

Psychosis from 2-FA

cognitiveStimulants

Psychosis + 2-FA

Effect category

cognitive

Substance class

Stimulants

Chemical class

Substituted amphetamines

Routes of administration

oral

Other effects from 2-FA

Other substances causing this effect

Psychosis + 2-FA

Effect category

cognitive

Substance class

Stimulants

Chemical class

Substituted amphetamines

Routes of administration

oral

Other 2-FA effects

Substances causing psychosis

2-FA is known to produce psychosis, a cognitive effect. Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — characterized by firmly held false beliefs (delusions), perception of things that are not there (hallucinations), disorganized thought and speech, and a loss of the ability to distinguish internal mental events from external reality.

About Psychosis

Psychosis represents one of the most severe adverse cognitive outcomes associated with psychoactive substance use. It is not a single symptom but a syndrome — a constellation of related disruptions to perception, belief, and thought that collectively produce a state in which the person has lost meaningful contact with shared reality. The defining features include delusions (fixed false beliefs maintained with absolute conviction),hallucinations (perceiving things that are not present, across any sensory modality),thought disorder (disorganized, incoherent, or tangential thinking and speech), andloss of insight (the inability to recognize that one's perceptions and beliefs are abnormal).

What distinguishes psychosis from the altered perceptions produced by a "normal" psychedelic or dissociative experience is fundamentally about insight. A person having a psychedelic trip may see geometric patterns overlay their visual field, but they know they have taken a substance and that the patterns are drug-induced. A person experiencing psychosis may see the same patterns but believe they represent coded messages from a government surveillance network — and no amount of rational argument can shake this conviction. The loss of the ability to reality-test one's own perceptions is the critical threshold that separates an altered state from a psychotic one.

Substance-induced psychosis can arise through several pathways. Acute intoxication psychosis can occur with high doses of psychedelics, stimulants, cannabis, and deliriants — the sheer intensity of the altered state overwhelms the person's capacity to maintain orientation.Stimulant psychosis is particularly well-documented: extended use of amphetamines, methamphetamine, or cocaine, especially combined with sleep deprivation, can produce a paranoid psychotic state that closely resembles acute schizophrenia, complete with persecutory delusions, auditory hallucinations, and disorganized behavior.Cannabis-induced psychosis can occur in predisposed individuals, sometimes after a single heavy exposure.Withdrawal psychosis can accompany withdrawal from alcohol and benzodiazepines.

The relationship between substance use and psychosis is bidirectional and complex. Substances can trigger psychotic episodes in individuals with latent vulnerability (genetic predisposition to schizophrenia-spectrum disorders), can worsen existing psychotic conditions, and can produce transient psychotic states in individuals with no underlying vulnerability. Cannabis use during adolescence has been identified as a significant risk factor for the later development of psychotic disorders, with a dose-response relationship. However, most people who use these substances never experience psychosis, and the interaction between substance exposure and individual vulnerability is not well enough understood to predict individual risk.

Harm reduction note: Psychosis is a psychiatric emergency. If someone has lost contact with reality — believing things that are clearly not true, acting on hallucinated perceptions, unable to recognize that they are intoxicated — they need professional help. Do not attempt to argue them out of delusions, as this typically escalates agitation. Ensure physical safety, speak calmly and simply, and call for medical assistance. Individuals with a personal or family history of psychotic disorders should exercise extreme caution with all psychoactive substances, particularly cannabis, psychedelics, and stimulants.

How 2-FA Produces This Effect

Although 2-FA has not been formally studied on the same level as traditional amphetamines, it is safe to assume that just like other substituted amphetamines with substitutions at similar positions (with the notable exception of 4-FA), it most likely acts primarily as both a dopamine and norepinephrine releasing agent. This means it effectively increases the levels of the norepinephrine and dopamine neurotransmitters in the brain by binding to and partially blocking the transporter proteins that normally clear those monoamines from the synaptic cleft. This allows dopamine and norepinephrine to accumulate within the brain to extra-endogenous levels, resulting in stimulating, motivating and euphoric effects.

In comparison to other substituted amphetamines, 2-FA is reported to be relatively free of side effects such as nausea, high blood pressure, anxiety and an uncomfortable offset ("comedown"). It is considered to be a functional and effective psychoactive substance for performing general productivity tasks in a manner that is similar to dextroamphetamine. However, at higher doses, it reportedly loses its productivity and attention-enhancing effects and begins to take on a recreational character due to the distracting euphoria and overstimulation that can result. However, it is often said that it possesses a "ceiling dose" that purportedly lowers the abuse threshold relative to methamphetamine, although this has yet to be scientifically demonstrated.

The toxicity and long-term health effects of recreational 2-exact toxic dosage is unknown. This is because 2-FA has very little history of human usage. Anecdotal evidence from people who have tried 2-FA within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). Others have commented that its d-isomer form is virtually similar to the effects of d-amphetamine, and thus far little has been shown to give reason to suspect that its toxicity is radically different (though future evidence to the contrary may prove otherwise).

It is perhaps worth noting that in the field of medicinal chemistry, the fluorine substitution is sometimes seen as desirable in central nervous system pharmaceutical agents, and is a common practice due to the corresponding increase in lipophilicity granted by the substitute.

It is strongly recommended that one use harm reduction practices when using this drug.

As with other stimulants, the chronic use of 2-moderately addictive with a high potential for abuse and is capable of causing psychological dependence among a certain population of users. When dependence or addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of 2-develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 10 days to be back at baseline (in the absence of further consumption). 2-FA presents cross-tolerance with Cross-all dopaminergic stimulants, meaning that after the consumption of 2-FA all stimulants will have a reduced effect (especially including atypical stimulants one might not expect, like MDMA due to its reliance on dopamine and norepinephrine to exert its full euphoric effect).

In a analogous way tolerance to amphetamine relates to tolerance on methamphetamine, 2-FA has been observed to have a similar relationship to its more popular relative, 2-FMA.

Psychosis

Abuse of compounds within the amphetamine chemical class at high dosages for prolonged periods of time can potentially result in a stimulant psychosis that may present with a variety of symptoms (e.g., paranoia, hallucinations, or delusions). A review on treatment for amphetamine, dextroamphetamine, and methamphetamine abuse-induced psychosis states that about 5–15% of users fail to recover completely. The same review asserts that, based upon at least one trial, antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis.

2-FA is currently a grey area compound within all parts of the world, meaning its regulation lies in a legal grey area and that it is not known to be specifically illegal ("scheduled") within any country. However, people may still be charged for its possession under certain circumstances such as under analogue laws and with intent to sell or consume.

Canada: 2-FA would be considered Schedule I as it is an analogue of Amphetamine.
China: As of October 2015 2-FA is a controlled substance in China.
France: As of december 2024, 2-FA is not explicitly scheduled. It is thus legal to possess, although in a grey area.
Germany: 2-FA is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
New Zealand: 2-FA is an amphetamine analogue, so is a Schedule 3 controlled substance in New Zealand.
Switzerland: 2-FA is a controlled substance specifically named under Verzeichnis E.
Turkey:** 2-FA is a classed as drug and is illegal to possess, produce, supply, or import.
The Netherlands:** 3-FA is a controlled substance as of July 1, 2025.
United Kingdom: 2-FA is considered a Class A drug as a result of the amphetamine analog clause of the Misuse of Drugs Act 1971.
United States: 2-FA may be considered to be an analogue of amphetamine under the Federal Analogue Act and thus a Schedule II drug. The Federal Analogue Act, 21 U.S.C. § 813, is a section of the United States Controlled Substances Act, allowing any chemical "substantially similar" to an illegal drug (in Schedule I or II) to be treated as if it were also in Schedule I or II, but only if it is intended for human consumption.
Responsible use
Designer drug
Stimulants
Substituted amphetamine
Amphetamine
2-FMA
3-FA
4-FA
2-FA (Wikipedia)
2-FA (Isomer Design)

2-FA can be administered via oral. The route of administration can influence both the onset and intensity of psychosis.

Psychosis from 2-FA

Psychosis + 2-FA

Psychosis + 2-FA

About Psychosis

How 2-FA Produces This Effect

Dosage Context

oral

Other Substances That Cause Psychosis (40)

Cannabinoid

Deliriant

Depressant

Dissociatives

Dissociatives, Psychedelic

Entactogen, Stimulants

Essential nutrient, Neurotransmitter cofactor

Neurotransmitter

Psychedelic

Stimulants

See Also

Frequently Asked Questions

Psychosis from 2-FA

Psychosis + 2-FA

Psychosis + 2-FA

About Psychosis

How 2-FA Produces This Effect

Dosage Context

oral

Other Effects from 2-FA (11)

Other Substances That Cause Psychosis (40)

Cannabinoid

Deliriant

Depressant

Dissociatives

Dissociatives, Psychedelic

Entactogen, Stimulants

Essential nutrient, Neurotransmitter cofactor

Neurotransmitter

Psychedelic

Stimulants

See Also

Frequently Asked Questions